Table 3.

Summary of Phase I trials designed to evaluate the tolerability and safety of ixabepilone in combination with biologic therapy in the management of solid tumors refractory to standard therapies, including pancreatic cancer^*

Reference	Patients enrolled (n)	Biologic agent pairing	Ixabepilone MTD	Reported survival
Kittaneh et al28	30	Sunitinib 37.5 mg orally, daily starting day 8 of cycle 1	Intravenous 20 mg/m2, days 1, 8, and 15 of a 28-day cycle or Intravenous 30 mg/m2, day 1 of a 21-day cycle	Eleven of 28 evaluable patients demonstrated partial response or stable disease
Herbolsheimer et al29	19	Dasatinib 100 mg orally daily	Intravenous 40 mg/m2, every 21 days	13 of 15 evaluable patients demonstrated partial response or stable disease

Note:

^*Survival data, reported as secondary objectives in these studies, are also summarized in this table.

Abbreviation: MTD, maximum tolerated dose.